Effects of endostatin on expression of vascular endothelial growth factor and its receptors and neovascularization in colonic carcinoma implanted in nude mice

World Journal of Gastroenterology

Volumn 10, Issue 22, 2004, Pages 3361-3364

  Jia, Yun He ^a,b   Dong, Xin Shu ^a   Wang, Xi Shan ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b JINLING HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; ENDOSTATIN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER INHIBITION; COLON CARCINOMA; CONTROLLED STUDY; DRUG EFFICACY; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TUMOR VASCULARIZATION; TUMOR VOLUME;

EID: 9744233613     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v10.i22.3361     Document Type: Article

References (29)

1. Potti A, Moazzam N, Tendulkar K, Javed NA, Koch M, Kargas S. Immunohistochemical determination of vascular endothelial growth factor (VEGF) overexpression in malignant melanoma. Anticancer Res 2003; 23: 4023-4026
2. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 24: 277-285
3. Nyberg P, Heikkila P, Sorsa T, Luostarinen J, Heljasvaara R, Stenman UH, Pihlajaniemi T, Salo T. Endostatin inhibits human tongue carcinoma cell invasion and intravasation and blocks the activation of matrix metalloprotease-2, -9, and -13. J Biol Chem 2003; 278: 22404-22411
4. Dkhissi F, Lu H, Soria C, Opolon P, Griscelli F, Liu H, Khattar P, Mishal Z, Perricaudet M, Li H. Endostatin exhibits a direct antitumor effect in addition to its antiangiogenic activity in colon cancer cells. Hum Gene Ther 2003; 14: 997-1008
5. Atiqur Rahman M, Toi M. Anti-angiogenic therapy in breast cancer. Biomed Pharmacother 2003; 57: 463-470
6. Sridhar SS, Shepherd FA. Targeting angiogenesis: a review of angiogenesis inhibitors in the treatment of lung cancer. Lung Cancer 2003; 42(2 Suppl): S81-S91
7. Uehara H. Angiogenesis of prostate cancer and antiangiogenic therapy. J Med Invest 2003; 50: 146-153
8. Schuch G, Kisker O, Atala A, Soker S. Pancreatic tumor growth is regulated by the balance between positive and negative modulators of angiogenesis. Angiogenesis 2002; 5: 181-190
9. Sim BK. Angiostatin and endostatin: endothelial cell-specific endogenous inhibitors of angiogenesis and tumor growth. Angiogenesis 1998; 2: 37-48
10. Kuroiwa M, Takeuchi T, Lee JH, Yoshizawa J, Hirato J, Kaneko S, Choi SH, Suzuki N, Ikeda H, Tsuchida Y. Continuous versus intermittent administration of human endostatin in xenografted human neuroblastoma. J Pediatr Surg 2003; 38: 1499-1505
11. Zachary I. VEGF signalling: integration and multi-tasking in endothelial cell biology. Biochem Soc Trans 2003; 31(Pt 6): 1171-1177
12. Qi L, Robinson WA, Brady BM, Glode LM. Migration and invasion of human prostate cancer cells is related to expression of VEGF and its receptors. Anticancer Res 2003; 23: 3917-3922
13. Karkkainen MJ, Haiko P, Sainio K, Partanen J, Taipale J, Petrova TV, Jeltsch M, Jackson DG, Talikka M, Rauvala H, Betsholtz C, Alitalo K. Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins. Nat Immunol 2004; 5: 74-80
14. Dales JP, Garcia S, Bonnier P, Duffaud F, Carpentier S, Djemli A, Ramuz O, Andrac L, Lavaut M, Allasia C, Charpin C. Prognostic significance of VEGF receptors, VEGFR-1 (Flt-1) and VEGFR-2 (KDR/Flk-1) in breast carcinoma. Ann Pathol 2003; 23: 297-305
15. Endo A, Fukuhara S, Masuda M, Ohmori T, Mochizuki N. Selective inhibition of vascular endothelial growth factor receptor-2 (VEGFR-2) identifies a central role for VEGFR-2 in human aortic endothelial cell responses to VEGF. J Recept Signal Transduct Res 2003; 23: 239-254
16. Pimenta FJ, Sa AR, Gomez RS. Lymphangiogenesis in human dental pulp. Int Endod J 2003; 36: 853-856
17. Kaipainen A, Korhonen J, Mustonen T, van Hinsbergh VW, Fang GH, Dumont D, Breitman M, Alitalo K. Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development PNAS. Proc Natl Acad Sci U S A 1995; 92: 3566-3570
18. Nakamura Y, Yasuoka H, Tsujimoto M, Yang Q, Imabun S, Nakahara M, Nakao K, Nakamura M, Mori I, Kakudo K. Flt-4-positive vessel density correlates with vascular endothelial growth factor-d expression, nodal status, and prognosis in breast cancer. Clin Cancer Res 2003; 9: 5313-5317
19. Van Trappen PO, Steele D, Lowe DG, Baithun S, Beasley N, Thiele W, Weich H, Krishnan J, Shepherd JH, Pepper MS, Jackson DG, Sleeman JP, Jacobs IJ. Expression of vascular endothelial growth factor (VEGF)-C and VEGF-D, and their receptor VEGFR-3, during different stages of cervical carcinogenesis. J Pathol 2003; 201: 544-554
20. Rehn M, Veikkola T, Kukk-Valdre E, Nakamura H, Ilmonen M, Lombardo CR, Pihlajaniemi T, Alitalo K, Vuori K. Interaction of endostatin with integrins; implicated in angiogenesis. Proc Natl Acad Sai U S A 2001; 98: 1024-1029
21. Guan KP, Ye HY, Yan Z, Wang Y, Hou SK. Serum levels of endostatin and matrix metalloproteinase-9 associated with high stage and grade primary transitional cell carcinoma of the bladder. Urology 2003; 61: 719-723
22. Sauter BV, Martinet O, Zhang WJ, Mandeli J, Woo SLC. Adenovirus-mediated gene transfer of endostatin in vivo results in high level of transgene expression and inhibition of tumor growth and metastases PNAS. Proc Natl Acad Sci U S A 2000; 97: 4802-4807
23. Oga M, Takenaga K, Sato Y, Nakajima H, Koshikawa N, Osato K, Sakiyama S. Inhibition of metastatic brain tumor growth by intramuscular administration of the endostatin gene. Int J Oncol 2003; 23: 73-79
24. Chen W, Fu J, Liu Q, Ruan C, Xiao S. Retroviral endostatin gene transfer inhibits human colon cancer cell growth in vivo. Chin Med J 2003; 116: 1582-1584
25. Sridhar SS, Shepherd FA. Targeting angiogenesis: a review of angiogenesis inhibitors in the treatment of lung cancer. Lung Cancer 2003; 42(2 Suppl): S81-S91
26. Plum SM, Hanson AD, Volker KM, Vu HA, Sim BK, Fogler WE, Fortier AH. Synergistic activity of recombinant human endostatin in combination with adriamycin: analysis of in vitro activity on endothelial cells and in vivo tumor progression in an orthotopic murine mammary carcinoma model. Clin Cancer Res 2003; 9: 4619-4626
27. Byrne AT, Ross L, Holash J, Nakanishi M, Hu L, Hofmann JI, Yancopoulos GD, Jaffe RB. Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model. Clin Cancer Res 2003; 9 5721-5728
28. Shibuya M. VEGF-receptor inhibitors for anti-angiogenesis. Nippon Yakurigaku Zasshi 2003; 122: 498-503
29. Tee D, DiStefano J 3rd. Simulation of tumor-induced angiogenesis and its response to anti-angiogenic drug treatment: mode of drug delivery and clearance rate dependencies. J Cancer Res Clin Oncol 2004; 130: 15-24